Harrow Health (HROW) Provides TRIESENCE Relaunch Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. SPY
3. META
4. ANT
5. FFAI
6. FFR
7. LLY
8. TSLA
9. FICO
10. CART

Go back to Harrow Health (HROW) Provides TRIESENCE Relaunch Update

Harrow Provides TRIESENCE® Relaunch Update

June 20, 2024 7:00 AM EDT

Successful Manufacture of TRIESENCE PPQ Batch Leads to Scheduling of Remaining Process Qualification Steps, Initial Inventory Build, and Pre-Commercial Activities

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to announce the successful manufacture of the first of three commercial-scale process performance qualification (PPQ) batches of TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid that is FDAapproved for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids.... More